Annual Cash & Cash Equivalents
$4.09 M
-$8.56 M-67.68%
December 31, 2023
Summary
- As of February 20, 2025, AMPE annual cash & cash equivalents is $4.09 million, with the most recent change of -$8.56 million (-67.68%) on December 31, 2023.
- During the last 3 years, AMPE annual cash & cash equivalents has fallen by -$13.26 million (-76.43%).
- AMPE annual cash & cash equivalents is now -91.87% below its all-time high of $50.32 million, reached on December 31, 2014.
Performance
AMPE Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$4.09 M
-$2.31 M-36.09%
December 31, 2023
Summary
- As of February 20, 2025, AMPE quarterly cash and cash equivalents is $4.09 million, with the most recent change of -$2.31 million (-36.09%) on December 31, 2023.
- Over the past year, AMPE quarterly cash and cash equivalents has dropped by -$8.56 million (-67.68%).
- AMPE quarterly cash and cash equivalents is now -94.77% below its all-time high of $78.23 million, reached on March 31, 2014.
Performance
AMPE Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
AMPE Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -67.7% | -67.7% |
| 3 y3 years | -76.4% | -76.4% |
| 5 y5 years | -46.1% | -46.1% |
AMPE Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -87.9% | at low | -87.9% | at low |
| 5 y | 5-year | -87.9% | at low | -87.9% | +69.3% |
| alltime | all time | -91.9% | -100.0% | -94.8% | -100.0% |
Ampio Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2023 | $4.09 M(-67.7%) | $4.09 M(-36.1%) |
| Sep 2023 | - | $6.40 M(-8.0%) |
| Jun 2023 | - | $6.95 M(-32.8%) |
| Mar 2023 | - | $10.35 M(-18.2%) |
| Dec 2022 | $12.65 M(-62.7%) | $12.65 M(-25.3%) |
| Sep 2022 | - | $16.95 M(-26.0%) |
| Jun 2022 | - | $22.89 M(-20.6%) |
| Mar 2022 | - | $28.84 M(-14.9%) |
| Dec 2021 | $33.89 M(+95.4%) | $33.89 M(+98.0%) |
| Sep 2021 | - | $17.12 M(-16.7%) |
| Jun 2021 | - | $20.55 M(+30.0%) |
| Mar 2021 | - | $15.80 M(-8.9%) |
| Dec 2020 | $17.35 M(+165.6%) | $17.35 M(+85.3%) |
| Sep 2020 | - | $9.36 M(+93.3%) |
| Jun 2020 | - | $4.84 M(+100.5%) |
| Mar 2020 | - | $2.42 M(-63.0%) |
| Dec 2019 | $6.53 M(-13.9%) | $6.53 M(-18.8%) |
| Sep 2019 | - | $8.04 M(-37.1%) |
| Jun 2019 | - | $12.78 M(+147.7%) |
| Mar 2019 | - | $5.16 M(-32.0%) |
| Dec 2018 | $7.58 M(-7.6%) | $7.58 M(-12.5%) |
| Sep 2018 | - | $8.67 M(+86.1%) |
| Jun 2018 | - | $4.66 M(-38.0%) |
| Mar 2018 | - | $7.52 M(-8.4%) |
| Dec 2017 | $8.21 M(+67.7%) | $8.21 M(+354.3%) |
| Sep 2017 | - | $1.81 M(-63.4%) |
| Jun 2017 | - | $4.94 M(+119.0%) |
| Mar 2017 | - | $2.26 M(-53.9%) |
| Dec 2016 | $4.89 M(-69.4%) | $4.89 M(-34.0%) |
| Sep 2016 | - | $7.42 M(+15.0%) |
| Jun 2016 | - | $6.45 M(-42.0%) |
| Mar 2016 | - | $11.11 M(-30.5%) |
| Dec 2015 | $16.00 M | $16.00 M(-54.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2015 | - | $35.38 M(-3.8%) |
| Jun 2015 | - | $36.78 M(-15.0%) |
| Mar 2015 | - | $43.27 M(-14.0%) |
| Dec 2014 | $50.32 M(+91.3%) | $50.32 M(-11.5%) |
| Sep 2014 | - | $56.83 M(-13.4%) |
| Jun 2014 | - | $65.64 M(-16.1%) |
| Mar 2014 | - | $78.23 M(+197.3%) |
| Dec 2013 | $26.31 M(+48.8%) | $26.31 M(-18.0%) |
| Sep 2013 | - | $32.07 M(+157.5%) |
| Jun 2013 | - | $12.46 M(-24.6%) |
| Mar 2013 | - | $16.53 M(-6.5%) |
| Dec 2012 | $17.68 M(+55.6%) | $17.68 M(-12.7%) |
| Sep 2012 | - | $20.27 M(+197.8%) |
| Jun 2012 | - | $6.80 M(-17.9%) |
| Mar 2012 | - | $8.29 M(-27.0%) |
| Dec 2011 | $11.36 M(+1592.6%) | $11.36 M(+62.5%) |
| Sep 2011 | - | $6.99 M(-16.5%) |
| Jun 2011 | - | $8.37 M(+83.7%) |
| Mar 2011 | - | $4.56 M(+579.1%) |
| Dec 2010 | $671.30 K(+832.4%) | $671.30 K(+5589.0%) |
| Sep 2010 | - | $11.80 K(-91.0%) |
| Jun 2010 | - | $131.00 K(-69.8%) |
| Mar 2010 | - | $433.30 K(+501.8%) |
| Dec 2009 | $72.00 K(+2471.4%) | $72.00 K(>+9900.0%) |
| Sep 2009 | - | $100.00(-90.9%) |
| Jun 2009 | - | $1100.00(-54.2%) |
| Mar 2009 | - | $2400.00(-14.3%) |
| Dec 2008 | $2800.00(+75.0%) | $2800.00(+250.0%) |
| Sep 2008 | - | $800.00(-83.0%) |
| Jun 2008 | - | $4700.00(+327.3%) |
| Mar 2008 | - | $1100.00(-31.3%) |
| Dec 2007 | $1600.00(>+9900.0%) | $1600.00(-82.8%) |
| Sep 2007 | - | $9300.00(>+9900.0%) |
| Dec 2006 | $0.00 | $0.00 |
FAQ
- What is Ampio Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Ampio Pharmaceuticals?
- What is Ampio Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Ampio Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Ampio Pharmaceuticals?
- What is Ampio Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Ampio Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of AMPE is $4.09 M
What is the all time high annual cash & cash equivalents for Ampio Pharmaceuticals?
Ampio Pharmaceuticals all-time high annual cash & cash equivalents is $50.32 M
What is Ampio Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, AMPE annual cash & cash equivalents has changed by -$8.56 M (-67.68%)
What is Ampio Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of AMPE is $4.09 M
What is the all time high quarterly cash and cash equivalents for Ampio Pharmaceuticals?
Ampio Pharmaceuticals all-time high quarterly cash and cash equivalents is $78.23 M
What is Ampio Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, AMPE quarterly cash and cash equivalents has changed by -$8.56 M (-67.68%)